Literature DB >> 7216423

Relationship of antibody to outcome in neonatal herpes simplex virus infections.

A S Yeager, A M Arvin, L J Urbani, J A Kemp.   

Abstract

Neutralizing antibody titers to herpes simplex virus type 1 (HSV-1) and HSV-2 were measured at birth in normal infants and uninfected infants of mothers with genital HSV infections during pregnancy and at the onset of infection in 5 infants with mild infections and 11 infants with severe infections. Thirty-eight percent of premature and 29% of term infants had neutralization titers of <1:5. High titers ([unk]1:40) were found in 55% of infants of mothers with primary infections during pregnancy and in 76% of infants of mothers with recurrent infections. The mean titers to HSV-1 and -2 in 5 infected infants with mild infections were 1:56 and 1:65 at the time of onset of infection, whereas the mean titers in 11 infants with severe infections were 1:11 and 1:12. Six natally exposed infants who remained asymptomatic were also studied and had a mean titer to HSV-1 of 1:85 and to HSV-2 of 1:69. Therefore, infants with high titers of transplacentally derived antibody had a more favorable outcome than infants with lower titers. Ninety-five percent of the infants of mothers with recurrent infections had a Rawls index of more than 85, suggesting that the antibody response was to HSV-2. However, low levels of antibody with this type specificity failed to protect four infants from infection with HSV-2. Augmentation of the neutralization titer to HSV-2 by the amount of complement present in cord serum was less than twofold. The study suggests that the quantity of antibody derived transplacentally affects the outcome of infection after natal exposure to herpes simplex virus. Complete neutralization of virus by antibody may occur in some infants, and prolongation of the incubation period and modification of the infection may occur in others.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7216423      PMCID: PMC551151          DOI: 10.1128/iai.29.2.532-538.1980

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Antiviral chemotherapy and neonatal herpes simplex virus infecition: a pilot study--experience with adenine arabinoside (ARA-A).

Authors:  L T Ch'ien; R J Whitley; A J Nahmias; E B Lewin; C C Linnemann; L D Frenkel; J A Bellanti; R A Buchanan; D A Alford
Journal:  Pediatrics       Date:  1975-05       Impact factor: 7.124

2.  Herpes genitalis: clinical features.

Authors:  H L Gardner; R H Kaufman
Journal:  Clin Obstet Gynecol       Date:  1972-12       Impact factor: 2.190

3.  Perinatal risk associated with maternal genital herpes simplex virus infection.

Authors:  A J Nahmias; W E Josey; Z M Naib; M G Freeman; R J Fernandez; J H Wheeler
Journal:  Am J Obstet Gynecol       Date:  1971-07-15       Impact factor: 8.661

4.  Measurement of antibodies to herpesvirus types 1 and 2 in human sera.

Authors:  W E Rawls; K Iwamoto; E Adam; J L Melnick
Journal:  J Immunol       Date:  1970-03       Impact factor: 5.422

5.  Hepres genitalis; clinical and cytopathologic experience with 256 patients.

Authors:  A B Ng; J W Reagan; S S Yen
Journal:  Obstet Gynecol       Date:  1970-10       Impact factor: 7.661

6.  Synergistic antiviral effects of adenine arabinoside and humoral antibodies in experimental encephalitis due to Herpesvirus hominis.

Authors:  C T Cho; K K Feng; N Brahmacupta
Journal:  J Infect Dis       Date:  1976-02       Impact factor: 5.226

7.  Passive immunization in experimental Herpesvirus hominis infection of newborn mice.

Authors:  F Luyet; D Samra; A Soneji; M I Marks
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

8.  Type specificity of complement-requiring and immunoglobulin M neutralizing antibody in initial herpes simplex virus infections of humans.

Authors:  N J Schmidt; B Forghani; E H Lennette
Journal:  Infect Immun       Date:  1975-10       Impact factor: 3.441

9.  Genital herpetic infection in men and women: clinical course and effect of topical application of adenine arabinoside.

Authors:  H G Adams; E A Benson; E R Alexander; L A Vontver; M A Remington; K K Holmes
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

10.  Prevention of cell-to-cell spread of herpes simplex virus by leukocytes.

Authors:  D L Lodmell; A Niwa; K Hayashi; A L Notkins
Journal:  J Exp Med       Date:  1973-03-01       Impact factor: 14.307

View more
  29 in total

1.  Prevention and management of neonatal herpes simplex virus infections.

Authors:  Upton D Allen; Joan L Robinson
Journal:  Paediatr Child Health       Date:  2014-04       Impact factor: 2.253

2.  Toward the rational management of herpes infection in pregnant women and their newborn infants. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1992-05-01       Impact factor: 8.262

3.  Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.

Authors:  A De Logu; R A Williamson; R Rozenshteyn; F Ramiro-Ibañez; C D Simpson; D R Burton; P P Sanna
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

Review 4.  Herpes simplex virus infections of the central nervous system. Encephalitis and neonatal herpes.

Authors:  R J Whitley
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

5.  Prevalence of antibodies to herpes simplex virus types 1 and 2 in pregnant women, and estimated rates of infection.

Authors:  A E Ades; C S Peckham; G E Dale; J M Best; S Jeansson
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

6.  Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity.

Authors:  Chaya D Patel; Iara M Backes; Sean A Taylor; Yike Jiang; Arnaud Marchant; Jean M Pesola; Donald M Coen; David M Knipe; Margaret E Ackerman; David A Leib
Journal:  Sci Transl Med       Date:  2019-04-10       Impact factor: 17.956

7.  Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity.

Authors:  Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib
Journal:  J Virol       Date:  2020-05-18       Impact factor: 5.103

8.  Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes.

Authors:  Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman
Journal:  Sci Immunol       Date:  2019-09-20

Review 9.  Neonatal herpes simplex infection.

Authors:  David W Kimberlin
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

10.  Guidance on management of asymptomatic neonates born to women with active genital herpes lesions.

Authors:  David W Kimberlin; Jill Baley
Journal:  Pediatrics       Date:  2013-01-28       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.